Day Traders, Penny Stocks, Stock Options, Futures and Forex

JohnBo · #1 (**permalink**) 01-07-2010, 04:13 AM

ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco

Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at ADVENTRX Pharmaceuticals. An archived presentation will be available on the Web site for 30 days

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's Web site at ADVENTRX Pharmaceuticals.

DATASOURCE: ADVENTRX Pharmaceuticals, Inc

CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX

Pharmaceuticals, +1-858-552-0866, or Investors, Don Markley of

Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for

ADVENTRX Pharmaceuticals, Inc

Web Site: ADVENTRX Pharmaceuticals

stewartlittle · #2 (**permalink**) 01-07-2010, 11:43 AM

Do you want 232% gainers.

Super Stock Picker

JohnBo · #3 (**permalink**) 01-08-2010, 12:33 AM

NEWS $$$$ ADVENTRX Pharmaceuticals Announces Closing of Financing

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series E convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19 million. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to the commercial launch of ANX-530, including acquiring or developing sales, marketing and distribution capabilities and the associated regulatory compliance infrastructure, and to continue the development of ANX-514 in the United States, and for general corporate purposes

The convertible preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $0.38115 per share and will accrue a 3.73344597664961% cumulative dividend until January 7, 2015. If the convertible preferred stock is converted at any time prior to January 7, 2015, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through January 7, 2015, or $186.67 per $1,000 stated value of convertible preferred stock converted, less any dividend payments made with respect to the converted convertible preferred stock. Approximately $3.5 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above

The investors also will receive warrants to purchase an aggregate of 12,462,285 shares of ADVENTRX's common stock. The warrants will have an exercise price of $0.3499 per share and are exercisable at any time after the closing of the transaction and before the thirty (30) month anniversary of the initial exercise date

The convertible preferred stock and warrants are being offered by ADVENTRX pursuant to effective registration statement(s) on Form S-3 filed with the Securities and Exchange Commission ("SEC"). A prospectus relating to the offering was filed with the SEC on January 4, 2010. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at U.S. Securities and Exchange Commission (Home Page)

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at ADVENTRX Pharmaceuticals

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the acceptance or approval of an ANX-530 NDA; the risk that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530, including validating commercial manufacturers and suppliers; the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to maintain sufficient stockholders' equity or a sufficient stock price; the risk that the provisions of Delaware General Corporation Law will prohibit ADVENTRX from making the cumulative dividend and other payments due its Series E convertible preferred stock (or to the holders thereof), which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data may be substandard, or they may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and in the prospectus relating to this offering that was filed with the Securities and Exchange Commission on January 4, 2010. ADVENTRX's public filings with the Securities and Exchange Commission are available at U.S. Securities and Exchange Commission (Home Page)

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

DATASOURCE: ADVENTRX Pharmaceuticals, Inc

CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX

Pharmaceuticals, +1-858-552-0866; or Investors, Don Markley of

Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for

ADVENTRX Pharmaceuticals, Inc

Web Site: ADVENTRX Pharmaceuticals

20 GOOD things about ANX:

FROM SOMEONE I TRUST

1) No debt
2) NOT a high float
3) GOOD pre-clinical test results with their drug.
4) NDA then FDA

JohnBo · #4 (**permalink**) 01-08-2010, 04:26 PM

NEWS $$ Press Release Source: Beacon Equity On Friday January 8, 2010, 6:50 am EST

DALLAS, Jan. 8, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company Adventrx Pharmaceuticals Inc. (AMEX:ANX - News). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: Beacon Equity Research

Get our alerts BEFORE the rest of the market. Follow us on Twitter: Beacon Equity (BeaconEquity) on Twitter

Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.

In the report, the analyst notes:

"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates, has a potential to reach more than $1.0 billion at market saturation.

"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."

To read the entire report visit: Beacon Equity Research

See what investors are saying about these stocks at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit Beacon Equity Research

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

JohnBo · #5 (**permalink**) 01-09-2010, 06:22 AM

ALL Longs need to watch this: http://www.adventrx.com/flash/Vinorelbine.swf

OneMedForum Finance Conference 2010
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

OneMedForum | OneMedPlace

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, we have added a third day dedicated to Health Information. Join us at The Sir Francis Drake Hotel, as it will be the destination for those who are interested in emerging healthcare and life sciences companies.

PRESENTING COMPANIES : Companies Presenting at the 2010 OneMedForum

ANX: ADVENTRX PHARMACEUTICALS INC Institutional Ownership

JohnBo · #6 (**permalink**) 01-09-2010, 08:51 AM

ANX / Link for Wednesday !

Webcast
ADVENTRX PHARMACEUTICALS INC at OneMedPlace Finance Forum (Live)
01/13/10 at 4:30 p.m. PT

ADVENTRX: Investors: Investor Relations Home
ADVENTRX: Investors: Event Details

JohnBo · #7 (**permalink**) 01-09-2010, 12:19 PM

M.E. Garza's article on ANX from December 29, 2009:

Adventrx Pharmaceuticals Gains Nearly 63%, Still Looking for More -- Seeking Alpha

A quote from BRIAN M. CULLEY (Principal Executive Officer) from a Wall Street interview held on October 19, 2009:

"TWST: How would you like to see the company evolve over the next couple of years?
Mr. Culley: We’re strongly committed to creating value for ADVENTRX stockholders. That might mean we will be acquired or will remain as an independent business, and we will make those determinations as we grow, but we will always make the decision that we believe maximizes our value on a risk-adjusted basis".

http://www.adventrx.com/assets/pdfs/...ct09-FINAL.pdf

JohnBo · #8 (**permalink**) 01-10-2010, 02:51 PM

Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors - tmackie -- Seeking Alpha

ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX)
ADVENTRX Pharmaceuticals
is a biopharmaceutical company founded in 1995 and based in San Diego, California, which focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. The Company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530, a novel emulsion formulation of chemotherapy drug Vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with Cisplatin, as well as to treat advanced or metastatic breast cancer.

If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions of cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."

The Company's Principal Executive Officer, Brian M. Culley, will be presenting at the OneMedForum Finance Conference on Wednesday, January 13, 2010. Mr. Culley will be discussing ANX-530 as well as another late-stage product candidate, ANX-514 (3 Billion existing market), which is a novel emulsion formulation of the chemotherapy drug Docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

When interviewed for this article, Principal Executive Officer, Brian Culley was asked about Carl Icahn's interest in the company. Mr. Culley confirmed, "We are well aware that Carl Icahn is a substantial stockholder in ADVENTRX." He went on to add, "In fact, the Icahn affiliates are entitled to have one seat on our board of directors."

Shares of ANX have been volatile amid news of takeover rumors recently reported by Fox Business. When asked about the takeover rumors, Mr. Culley responded, "No comment." This will only serve to fuel the speculation.

Disclosure: Disclosure: Long ANX

JohnBo · #9 (**permalink**) 01-10-2010, 04:20 PM

SOMETHING BIG IS COMING

PRESIDENT COMMENTS ON TAKE-OVER

Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors - tmackie -- Seeking Alpha

JohnBo · #10 (**permalink**) 01-10-2010, 07:02 PM

Article just out on ANX - LINK attached!
Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors

Make sure to hit the "buzz up" button on the top right.

Or hit buzz up here:
Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors - newsblaze.com - Yahoo! Buzz

It's the real deal, guys. This is a great article for LONGS. Again, Buzz it up so it gets to most popular.

You can also find it on Google Finance:
News for ADVENTRX Pharmaceuticals, Inc. - Google Finance

Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors:

ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) is a biopharmaceutical company founded in 1995 and based in San Diego, California, which focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. The Company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530, a novel emulsion formulation of chemotherapy drug Vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with Cisplatin, as well as to treat advanced or metastatic breast cancer.

If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions in cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."

The Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010. Mr. Culley will discuss ANX-530 as well as another late-stage product candidate, ANX-514 (3 Billion existing market), which is a novel emulsion formulation of the chemotherapy drug Docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

When interviewed for this article, Principal Executive Officer, Brian Culley was asked about Carl Icahn's interest in the company. Mr. Culley confirmed, "We are well aware that Carl Icahn is a substantial stockholder in ADVENTRX." He went on to add, "In fact, the Icahn affiliates are entitled to have one seat on our board of directors."

Shares of ANX have been volatile amid news of takeover rumors recently reported by Fox Business. When asked about the takeover rumors, Mr. Culley responded, "No comment." This will only serve to fuel the speculation.

Traci Hogg is a small stock trader and business writer, who specializes in investigating successful OTC companies.

Disclosure: Writer is Long ANX, but receives no compensation from the company

LINK:
Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode